• Wnt Agonist 1 (BML-284): Mechanism & Use

  2026-08-17

  Wnt agonist 1, also called BML-284, is a small-molecule activator of β-catenin-dependent TCF transcription with a reported EC50 of approximately 0.7 μM. It is a research tool for Wnt pathway cellular differentiation research and for testing whether canonical Wnt signaling influences disease-associated transcriptional programs.

• ACE2 Activation in Sepsis Cardiomyopathy

  2026-08-16

  The February 2024 reference study identifies ACE2 downregulation as a feature of sepsis-induced cardiomyopathy and links ACE2 activation to MasR-Sirt1-mediated mitochondrial biogenesis. Using complementary pharmacological activation and inhibition in a mouse CLP model, the work connects mitochondrial preservation with improved cardiac function, inflammation, oxidative stress, and apoptosis outcomes.

• Geneticin (G-418 Sulfate): Selection and Evidence

  2026-08-15

  Geneticin, also called G418 Sulfate, is an aminoglycoside selection antibiotic that inhibits eukaryotic 80S ribosome-dependent protein synthesis. Its strongest routine use is selecting cells with a compatible neomycin-resistance gene, while product information also reports assay-specific antiviral activity against Dengue virus serotype 2.

• MLN2238: From Proteasome Inhibition to Stress Sensing

  2026-08-15

  MLN2238 is more than a potent proteasome β5 subunit inhibitor: it is a mechanistic probe for connecting proteotoxic stress with ROS, JNK, and CREB signaling. This thought-leadership guide translates its biochemical selectivity into experimental strategy for multiple myeloma research, lymphoma research, resistance studies, and emerging proteostasis models.

• In Vitro Drug Response Metrics in Cancer Research

  2026-08-14

  Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell killing, helping researchers design more informative in vitro studies and interpret Salinomycin and other candidate treatments with greater precision.

• Tigecycline and CREC: From Genes to Assays

  2026-08-14

  Explore how Tigecycline, a glycylcycline antibiotic, can serve as an orthogonal phenotypic probe in carbapenem-resistant Enterobacter cloacae research. This article connects plasmid transmission data with assay design, interpretation, and translational limitations.

• Ridaforolimus in Senescence Assay Design

  2026-08-13

  Ridaforolimus and Deforolimus provide a precise pharmacological probe for mTOR-dependent growth, translation, angiogenesis, and senescence-associated phenotypes. This guide explains how to distinguish pathway suppression from true senolysis and design more informative oncology assays.

• Pyridostigmine, α7nAChR, and Placental Necroptosis

  2026-08-13

  The reference study identifies placental necroptosis as a pharmacologically tractable component of preeclampsia-like pathology in rats. By combining pyridostigmine treatment with α-bungarotoxin and necrostatin-1 controls, the authors link enhanced non-neuronal cholinergic signaling to reduced necroptosis, oxidative stress, inflammation, and trophoblast dysfunction.

• 17-AAG: HSP90 Inhibition Meets NINJ1 Biology

  2026-08-12

  17-AAG (Tanespimycin) is a powerful HSP90 inhibitor for dissecting oncogenic client-protein stability and apoptosis. This article connects its cancer-research applications with new NINJ1-dependent secretion biology while emphasizing assay controls that distinguish protein export from nonspecific membrane rupture.

• Lypressin Acetate: Workflows for GPCR Research

  2026-08-12

  Lypressin acetate is a multifunctional vasopressin analog for receptor signaling, antidiuretic models, vascular contractility studies, and exploratory antiviral screening. This practical guide connects its quantified activities with assay design, handling controls, and troubleshooting strategies that improve reproducibility.

• PDGF-BB, Murine Recombinant Protein Guide

  2026-08-11

  A scenario-based guide to using PDGF-BB, murine recombinant protein in proliferation, viability, and cytotoxicity workflows. It explains how SKU P1048 supports controlled dose selection, receptor-aware experimental design, low-endotoxin handling, and clearer interpretation of smooth muscle cell data.

• Gemcitabine HCl: From Cytotoxicity to MRI Endpoints

  2026-08-10

  Gemcitabine HCl research is strongest when molecular cytotoxicity data are connected to anatomically rigorous tumor measurements. This guide explains how to align cell assays, treatment schedules, and multianimal MRI in pancreatic cancer studies without confusing pharmacologic response with measurement variability.

• Cepharanthine: Designing Stronger Translational Assays

  2026-08-09

  Cepharanthine is a biscoclaurine alkaloid with apoptosis, DNA-damage, and immunomodulatory research relevance. This article presents an evidence-tiered strategy for selecting assays, interpreting organoid data, and translating preclinical findings without overstating clinical maturity.

• Hypoxia, Choroid Plexus, and Cognitive Impairment

  2026-08-08

  A 2026 mouse study identifies choroid plexus barrier disruption and M1 macrophage polarization as central features of hypoxia-induced cognitive impairment. Its proposed AMPK–oxidative stress–immune cascade provides a framework for studying how systemic oxygen deficiency alters blood–cerebrospinal fluid barrier function and CNS homeostasis.

• Imatinib (STI571): Kinase Inhibition Guide

  2026-08-07

  Imatinib, also called STI571, is a selective protein-tyrosine kinase inhibitor for Abl, PDGF receptors, and c-Kit. Its defined kinase activity and pathway effects make it useful for signal transduction research, cancer biology research, and controlled studies of proliferative signaling.

455 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page